Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ELX-02 in Renal Impairment
NCT03776539Phase 1Completed
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of exaluren in cystic fibrosis (CF) and nephropathic cystinosis (4 arms). Primary endpoints: Plasma Area Under the Concentration-Time Curve from 0 to 24 hours, Plasma Maximum Concentration and 5 more. Started Jan 2019; status: completed.
02
Drugs
exaluren
03
Conditions
cystic fibrosis (CF)nephropathic cystinosis
Beyond the preview
Go deeper on NCT03776539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776539.